Copyright © 2015 American Chemical Society
 

March 9, 2015 Issue

Volume 93, Issue 10
09310-cover-openeralternate
March 9, 2015 Issue, Vol. 93 | Iss. 10
Chemistry is still key to the drug industry’s fortunes
By Ann M. Thayer
(pp. 11-19)
Features
Business
U.S. chemical producers are wobbling a little after an oil price decline but are still on their feet  (pp. 27-28)
Science & Technology
3-D bioprinting can already create living tissue, but it’s unclear whether it will ever replicate organs (pp. 37-39)
Back Issues
 

News of the Week

Helping Brains Relieve Anxiety

Neuroscience: Phosphatase inhibitor restores regulatory circuit
(p.5)

Abbvie Wins Pharmacyclics

Pharmaceuticals: $21 billion deal helps firm become a leader in treating blood cancers
(p.6)

Climate-Friendly Refrigerants

Regulation: EPA approves five products that have low potentials for global warming
(p.6)

Ancient Mars Had Enough Water For A Giant Ocean

New data suggest 20% of Red Planet’s surface was covered by ocean
(p.7)

European Chemical Firms Struggle To Secure Growth

Finance: Outlook for 2015 remains uncertain
(p.7)

White House Taps Transportation Official To Head Chemical Safety Board

Embattled organization has been beset by management woes, departures
(p.8)

AstraZeneca Will Spin Off Antibiotics

Drug Discovery: Stand-alone company to be formed after no buyers emerge for business
(p.9)

Computational Models Of Multistep Reaction Are Called So Flawed They Are ‘Not Even Wrong’

Reaction Chemistry: Study reveals mechanism theoretical work didn’t predict
(p.9)
 

Departments

09310-bus4-Pryorcxd

Business

Career oilman reflects on the past four decades and the keys to his company’s success in chemicals
(p.29)
Large firms saw their portfolios hold up against pricing pressures and uneven demand growth
(pp. 23-24)
U.S. chemical producers are wobbling a little after an oil price decline but are still on their feet
(pp. 27-28)
Biotech drug firms saw substantial growth as their big pharma competitors struggled
(pp. 25-26)
Chemistry is still key to the drug industry’s fortunes
(pp. 11-19)